Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients

Y Nakamura,K Namikawa,K Yoshino,S Yoshikawa,H Uchi, K Goto,Y Nakamura,S Fukushima, Y Kiniwa,T Takenouchi,H Uhara,T Kawai,N Hatta,T Funakoshi,Y Teramoto,A Otsuka,H Doi,D Ogata,S Matsushita,T Isei,T Hayashi, Y Shibayama, N Yamazaki

Annals of Oncology（2020）

引用 93|浏览88

暂无评分

摘要

•Acral melanoma is a distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma.•We retrospectively examined advanced-stage acral melanoma patients treated with an anti-PD-1 antibody.•Anti-PD-1 antibodies have limited efficacy in Japanese acral melanoma patients.•Patients with nail apparatus melanoma had poorer response and survival than patients with palm and sole melanoma.

查看译文

关键词

acral melanoma,anti-PD-1 antibody,efficacy,malignant melanoma,nivolumab,pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要